BioStem Technologies, Inc. BSEM
1.04 USD -0.12 (-10.34%)
At closeNov 5, 2026, 4:03 PM EST
1.05 +0.01 +0.96%
After hours · Nov 5, 4:03 PM ET
1.01 Day range 1.17
1.01 52-week range 8.40
- YTD
- -72.70%
- 1 year
- -74.63%
News
globenewswire.com BioStem Technologies to Host Third Quarter 2026 Financial Results Conference Call on November 12, 2026 POMPANO BEACH, Fla., Oct. 29, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development,…
prismmediawire.com BioStem Technologies' CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options Leadership investment supports expanded hospital commercial push PR Audio: POMPANO BEACH, Fla., October 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem…
globenewswire.com BioStem Technologies' CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options POMPANO BEACH, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development,…
defenseworld.net Century Therapeutics (NASDAQ:IPSC) and BioStem Technologies (OTCMKTS:BSEM) Financial Analysis Century Therapeutics (NASDAQ: IPSC - Get Free Report) and BioStem Technologies (OTCMKTS:BSEM - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will…
benzinga.com BioStem Secures US Patent, Additional US And Mexico Allowances For Tissue Technologies BioStem Technologies, Inc. (NASDAQ:BSEM) ("BioStem" or the "Company"), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue
prismmediawire.com BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio Newly issued U.S. Patent and pending allowances in the U.S. and Mexico extend protection for the company's sterile placental allograft, micronized wound care, and umbilical cord extract technologies…
globenewswire.com BioStem Technologies Strengthens Placental Allograft and Umbilical Tissue Patent Portfolio POMPANO BEACH, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development,…
prismmediawire.com BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules POMPANO BEACH, Fla., September 30, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies Inc.
globenewswire.com BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development,…
globenewswire.com Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform West Palm Beach, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers IM Cannabis (NASDAQ:IMCC) stock increased by 246.0% to $6.02 during Friday's regular session. The market value of their outstanding shares is at $1.0 million. SkyAI (NASDAQ:SKYA) stock rose…
prismmediawire.com BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility PR Audio: PR Video Overview: POMPANO BEACH, Fla., September 18, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
globenewswire.com BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility POMPANO BEACH, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development,…
prismmediawire.com BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier Additions extend BioStem's hospital channel to its BioRetain® wound care line PR Audio: POMPANO BEACH, Fla., September 4, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) –…
globenewswire.com BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier POMPANO BEACH, Fla., Sept. 04, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development,…
globenewswire.com BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference POMPANO BEACH, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development,…
marketbeat.com BioStem Technologies Eyes Surgical Growth, Manufacturing Shift After BioTissue Deal BioStem Technologies OTCMKTS: BSEM outlined its strategy to expand in surgical applications, shift its revenue mix away from physician-office wound care and bring manufacturing of acquired products…
defenseworld.net Comparing BioStem Technologies (OTCMKTS:BSEM) and Enlivex Therapeutics (NASDAQ:ENLV) BioStem Technologies (OTCMKTS:BSEM - Get Free Report) and Enlivex Therapeutics (NASDAQ: ENLV - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will…
globenewswire.com BioStem Technologies to Present at the Sidoti MicroCap Conference POMPANO BEACH, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development,…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regular session. The market value of their outstanding shares is at $7.2 million. BeyondSpring (NASDAQ:BYSI)…
marketbeat.com BioStem Technologies Q2 Earnings Call Highlights BioStem Technologies OTCMKTS: BSEM reported second-quarter revenue of $7.9 million as the company continued its transition to a predominantly hospital-focused commercial model. Revenue increased from…
seekingalpha.com BioStem Technologies, Inc. (BSEM) Q2 2026 Earnings Call Transcript BioStem Technologies, Inc. (BSEM) Q2 2026 Earnings Call Transcript
zacks.com BioStem Technologies, Inc. (BSEM) Reports Q2 Loss, Beats Revenue Estimates BioStem Technologies, Inc. (BSEM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to earnings of $0.11 per share a year ago.
benzinga.com BioStem Technologies Q2 EPS $(0.52), Sales $7.899M Down From $10.963M YoY BioStem Technologies (NASDAQ:BSEM) reported quarterly losses of $(0.52) per share. The company reported $7.899 million in sales this quarter. This is a 27.95 percent decrease over sales of $10.963…
benzinga.com BioStem Technologies Announces It Received Nasdaq Approval For The Company’s Common Stock For Listing On The Nasdaq Capital Market; Co. To Begin Trading On Nasdaq On August 7, 2026 Under The Ticker Symbol "BSEM" BioStem Technologies Inc. (OTC:BSEM) ("BioStem" or the "Company"), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue…
benzinga.com Biostem Technologies Files Form 10 Share Registration Statement With The SEC; Reaffirms Planned Nasdaq Listing "The filing of our Registration Statement is an important milestone that advances our path toward a Nasdaq uplisting and reflects our significant commitment to operating as an SEC reporting company,"…- benzinga.com NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova Allograft NovaBay Pharmaceuticals, Inc. (NYSE:NBY) and BioStem Technologies, Inc. (OTC:BSEM) announce an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies' Amniotic…
- benzinga.com EXCLUSIVE: BioStem Technologies Reports Q1 Net Revenue Up 211% YoY BioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics today, reported financial results…